Australia's most trusted
source of pharma news
Thursday, 20 March 2025
Posted 27 March 2024 AM
Two Australian companies have announced good news from the FDA this week.
West Australian biotech Argenica Therapeutics has been granted a Rare Pediatric Disease Designation (RPDD) by the FDA for its flagship product ARG-007 for the treatment of Hypoxic Ischaemic Encephalopathy (HIE) in newborn term infants.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.